Roles of the Amino Terminal Region and Repeat Region of the *Plasmodium berghei* Circumsporozoite Protein in Parasite Infectivity

Cassandra Aldrich1,2,3, Alessandro Magini1, Carla Emiliani1, Tania Dottorini1, Francesco Bistoni1, Andrea Crisanti1,2, Roberta Spaccapelo1*

1 Department of Experimental Medicine, University of Perugia, Perugia Italy, 2 Department of Life Sciences, Imperial College London, London, United Kingdom, 3 Keble College, University of Oxford, Oxford, United Kingdom

**Abstract**

The circumsporozoite protein (CSP) plays a key role in malaria sporozoite infection of both mosquito salivary glands and the vertebrate host. The conserved Regions I and II have been well studied but little is known about the immunogenic central repeat region and the N-terminal region of the protein. Rodent malaria *Plasmodium berghei* parasites, in which the endogenous Cs gene has been replaced with the avian *Plasmodium gallinaceum* Cs (PgCS) sequences, develop normally in the *A. stephensi* mosquito midgut but the sporozoites are not infectious. We therefore generated *P. berghei* transgenic parasites carrying the PgCS gene, in which the repeat region was replaced with the homologous region of *P. berghei* CS (PbCS). A further line, in which both the N-terminal region and repeat region were replaced with the homologous regions of PbCS, was also generated. Introduction of the PbCS repeat region alone, into the PgCS gene, did not rescue sporozoite species-specific infectivity. However, the introduction of both the PbCS repeat region and the N-terminal region into the PgCS gene completely rescued infectivity, in both the mosquito vector and the mammalian host. Immunofluorescence experiments and western blot analysis revealed correct localization and proteolytic processing of CSP in the chimeric parasites. The results demonstrate, *in vivo*, that the repeat region of *P. berghei* CSP, alone, is unable to mediate sporozoite infectivity in either the mosquito or the mammalian host, but suggest an important role for the N-terminal region in sporozoite host cell invasion.

**Citation:** Aldrich C, Magini A, Emiliani C, Dottorini T, Bistoni F, et al. (2012) Roles of the Amino Terminal Region and Repeat Region of the *Plasmodium berghei* Circumsporozoite Protein in Parasite Infectivity. PLoS ONE 7(2): e32524. doi:10.1371/journal.pone.0032524

**Editor:** Tobias Spielmann, Bernhard Nocht Institute for Tropical Medicine, Germany

**Received** July 22, 2011; **Accepted** January 29, 2012; **Published** February 29, 2012

**Copyright:** © 2012 Aldrich et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by grants from the Italian Ministry of Research PRIN (Research Programmes of National Interest) n. 2005065913. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

* E-mail: roberta.spaccapelo@unipg.it

**Introduction**

The circumsporozoite protein (CSP) is the predominant surface antigen of *Plasmodium* sporozoites and is highly immunogenic being one of the key targets recognised by the host immune system. Pre-erythrocytic malaria vaccines have been primarily based on CSP [1,2]. In particular, the central repeat region of *P. falciparum* CSP, which contains an immunodominant B cell epitope, represented the target of the first two vaccine trials [3,4]. Recently, the results of a phase III trial of the RTS,S vaccine, based on both the repeat region and T-cell epitopes from the C-terminal region, provided evidence for protection against both clinical and severe malaria in African children [5].

CSP performs numerous functions for the sporozoite at different stages in the life cycle. The protein is first detected at high levels in the oocyst and has been shown to be vital in the process of sporogony [6,7]. CSP is likely to be important in sporozoite gliding motility although the precise role that the protein plays in gliding remains unknown. Antibodies against CSP inhibit gliding motility [8] and sporozoites leave behind trails of CSP that correspond to their pattern of movement [9]. CSP has long been known to be involved in sporozoite infectivity [10,11]. Specifically, it appears to be important in the binding of the sporozoite to both mosquito salivary glands [12,13,14] and vertebrate host hepatocytes [15,16,17].

Comparison of the deduced amino acid sequences of CS proteins from all species of *Plasmodium* shows that they have a similar overall structure. They all contain a central repeat region, whose amino acid sequence is species specific, and two conserved regions: a five amino acid sequence called Region I (RI), immediately upstream of the repeats, and a known cell-adhesive sequence with similarity to the type I repeat of thrombospondin called Region II (RII), downstream of the repeat region. CSP has a canonical glycosylphosphatidylinositol (GPI) anchor addition sequence in its C-terminus. Much evidence has been gathered on the functions of the conserved Regions I and II of CSP, as well as on residues outside of RI and RII, within the N- and C-terminal portions of the protein, which have been implicated in host binding [18,19,20,21]. However, little evidence exists to date on the role of the CSP repeat region in the parasite life cycle.

The RI core is a five amino acid sequence (KLKQP), conserved in almost all *Plasmodium* species with the exception of the avian malaria parasite *P. gallinaceum*, in which there are two amino acid changes in the core (NLNQP) (Figure 1). RI has been strongly
implicated in the binding of salivary glands [13,22]. A peptide encompassing RI was shown to inhibit binding of both recombinant CSP and sporozoites to the salivary glands. However, the RI core alone could not achieve this inhibition and upstream residues were also required [13,22]. The sequence upstream of RI contains stretches of positively charged residues which are implicated, together with RI, in the interaction with liver heparan sulphate proteoglycans (HSPGs) [19,21]. RI and RII peptides inhibited P. falciparum CSP (PfCSP) binding to HepG2 cell HSPGs to a similar extent, suggesting they both contribute to the interaction [23]. RII is a common motif present in the proteins of a wide range of organisms and is also found in another sporozoite surface protein, the thrombospondin-related adhesive protein (TRAP). It is an 18 amino acid region and part of a larger type I repeat of human thrombospondin (TSR) domain which acts as an adhesive module and binds with high affinity to heparin and certain sulphated glycoconjugates (Figure 1). The rapid and specific homing to the liver by sporozoites of mammalian Plasmodium spp. has been ascribed to the interaction between RII and glycosaminoglycan (GAG) side chains on HSPGs, located on the basolateral surface of hepatocytes [15,16,23,24,25]. The only difference between the P. gallinaceum RII and the RII consensus, present in all Plasmodium species, is a single amino acid substitution, despite the fact that P. gallinaceum does not infect hepatocytes.

The repeat region is species-specific, immunodominant and constitutes about one half of the molecule. It contains multiple copies of tandemly arrayed repeat peptides (Figure 1) and has no obvious sequence homology to any known protein. The repeats contain B-cell immunodominant epitopes and antibodies specific to this region can protect against malaria by blocking sporozoite invasion of host hepatocytes [26,27]. The function of the CSP repeat region within the parasite life cycle has so far not been investigated. However, there are reasons to believe that this large domain of CSP could perform perhaps multiple functions for the parasite. The repeat peptide structure might lend itself well to high avidity interactions with host receptors, for example GAGs which are composed of repeating sugar units. Multivalency is able to enhance the affinity of protein-carbohydrate interactions, particularly those involving GAGs [28], and the repeats could provide multivalent binding sites. In addition, the species-specific nature of the region may indicate a role in maintaining the host specificity of infection.

P. berghei parasites, in which the entire CS gene (PbCS) was replaced with its P. gallinaceum orthologue, failed to invade

![Figure 1. Schematic representation and alignment of wild type and transgenic P. berghei circumsporozoite proteins.](image-url)

(A) Schematic representation of the CS proteins present in each of the four transgenic P. berghei parasite lines generated. The corresponding names of the transgenic parasite lines are shown on the right. PbCS\textsuperscript{DHFR} parasites carry the wildtype PbCS coding sequence (white boxes, RI and RII indicated with light and dark green respectively) and, similar to all transgenic lines, contain the T. gondii DHFR drug selectable marker inserted in the CS locus. PgCS\textsuperscript{x} parasites carry the full PgCS coding sequence (grey boxes, RI and RII indicated with light and dark blue respectively), but with the SpeI (S) and Xhol (X) restriction endonuclease sites inserted on either side of the repeat region. PgCS/Pb\textsuperscript{RR} parasites carry the PbCS N-terminal and repeat regions (white boxes) and the PgCS C-terminal region (grey box). (B) Alignment of the wild type PbCS and transgenic PgCS\textsuperscript{x} and PgCS/Pb\textsuperscript{RR} amino acid sequences. Shaded boxes represent areas of amino acid identity. Regions I and II (black lines), the repeat region (blue line) and the SpeI and Xhol restriction sites (red lines) are labelled. The SpeI and Xhol sites were introduced into the PgCS sequence to mediate exchange of the PgCS repeat region with the PbCS repeat region.

doi:10.1371/journal.pone.0032524.g001
salivary glands and to infect mice [29], although sporozoite development and CSP expression appeared unaffected. *P. gallinaceum* is carried by the mosquito vector *Aedes aegypti* whereas *P. berghei* is carried by anopheline vectors. The lack of infectivity with the *PgCS* replacement parasites could be due to the inability of PgCSP to bind to *A. stephensi* salivary gland receptors and rodent liver receptors.

To assess whether the repeat region has a role in salivary gland or vertebrate infectivity, we generated transgenic *P. berghei* parasites carrying the *PgCS* gene, in which the repeat region was replaced with the *PbCS* repeat region (Figure 1), in order to determine if introduction of the wild-type sequence rescues infectivity. Another parasite line containing the full-length *PgCS* N-terminal sequence (up to RI), the *PbCS* repeat region and the *PgCS* C-terminal sequence was also generated and allowed further analysis of the role of the N- and C-terminal regions (Figure 1).

**Results**

**Generation of transgenic parasites**

Transgenic *P. berghei* parasites were generated that carried chimeric *P. gallinaceum - P. berghei* CS genes. In the first transgenic parasite line, the endogenous *PbCS* gene was substituted with the *PgCS* gene in which the repeat region was replaced with the homologous region of *P. berghei*: line *PgCS/PbRR* (Figure 1A). A second line contained both the N-terminal region and repeat region of *P. berghei*, while the C-terminal region was replaced with the homologous sequence of *P. gallinaceum*: line *PbCS/PgCT* (Figure 1A). As controls, we generated: i) a transgenic line carrying the wild type *PbCS* gene and the drug selectable marker inserted in the *PbCS* locus: line *PbCS/DHFR* and ii) a transgenic line carrying the *PgCS* gene in which the *Spel* and *Xhol* restriction sites had been introduced on either side of the repeat region: line *PgCS*SN (Figure 1A). A schematic representation and alignment of *PbCSP* and the CS proteins expressed in the transgenic parasites, and their corresponding names, are presented in Figure 1A and 1B respectively.

The targeting constructs were designed to direct the double cross-over event between the 1.15 kb sequence of the *PbCS* 5′ untranslated region (UTR) and the 0.85 kb sequence of the *PbCS* 3′ UTR in the linearized plasmid and their corresponding sequences in the *PgCS* locus (Figure 2A and Figure S1A). Two targeting constructs, *pPgCS/PbRR* and *pPgCS*SN were then used to transfect *P. berghei* wild type (Pbwt) parasites (Figure 2A and Figure S1A respectively).

In construct *pPgCS*SN (Figure S1A), the *Spel* and *Xhol* restriction sites had been introduced by site-directed mutagenesis into the *PgCS* sequence in order to mediate exchange of the *PgCS* repeat region with the homologous sequence of *P. berghei*. The *Spel* site was inserted immediately downstream of the *PgCS* RI core sequence, *NNQNP* (Figure 1). The *Xhol* restriction site was inserted after the *PgCS* repeat region and before RI (Figure 1). Correct insertion of the construct, to generate the control transgenic parasite line *PgCS*SN (clones 1 and 2), was confirmed by Southern blot analysis (Figure S1).

A second construct was generated by replacing the *PgCS* repeat region in *pPgCS*SN with the *PbCS* repeat region, which had been amplified from genomic DNA. The resulting construct, *pPgCS/PbRR*, was then transfected into Pbwt parasites to create the transgenic line *PgCS/PbRR* (clones 4 and 5), and correct integration was confirmed by southern blot (Figure 2).

Other integration events were also observed after transformation with the *pPgCS/PbRR* vector, as a consequence of cross-over events that took place between sequences present in the internal part of the construct and the homologous sequences in the *PbCS* locus. This resulted in the generation of two further transgenic parasite lines, *PgCS/PgCT* and *PgCS/PbDHFR* (Figure 3 and Figure S2). *PbCS/PgCT* clones 3 and 6 originated from cross-over events at the 0.5 kb *PbCS* repeat region and the 3′ UTR sequence (Figure 3A). The *PbCS/PgCT* parasite line generated therefore contained a chimeric CS gene where both the N-terminal sequence and the repeat region were from *P. berghei*, while the C-terminal sequence was from *P. gallinaceum*, as demonstrated by Southern blot analysis (Figure 3).

Moreover, just 300 bp of the *PgCS* 3′ UTR, present between the chimeric CS gene and the *TgDHFR/TS* cassette in the construct *pPgCS/PbRR* was sufficient to direct recombination, generating the *PgCS/DHFR* transgenic line (Figure S2A). Double cross-over recombination, between the two *PbCS* 3′ UTR regions present in the construct and the homologous regions in the *PbCS* locus, resulted in the insertion of only the *TgDHFR/TS* cassette, in the 3′ UTR region of the *PgCS* locus, leaving the endogenous *PbCS* gene intact. The transgenic *PgCS/DHFR* clones 9 and 10 generated (Figure S2) were used as a control for any phenotypic effects arising from the presence of the selectable marker cassette within the CS locus.

The insertion events described, and the presence of the correct CS gene sequences in the transgenic parasites lines, was further confirmed by sequencing the CS genes, which had been PCR amplified from genomic DNA.

**Development of the transgenic parasites in the mosquito vector**

Blood stage parasites from all transgenic lines replicated normally in mice and *in vitro* generated gametocytes that developed into fertile gametes. The development of the transgenic parasites in the mosquito was monitored in *A. stephensi* fed on infected mice. Mosquito midguts infected with each of the transgenic clones, and dissected at 14 and 18 days post-infection (p.i.), revealed normal oocyst development compared to midguts infected with Pbwt parasites. All transgenic oocysts had the same morphology as Pbwt oocysts. Interestingly, melanisation observed in midguts infected with *PgCS*-replacement *P. berghei* parasites [29] was only seen in midguts infected with transgenic lines containing *PgCS* sequences. However, it occurred with a very low frequency both in terms of the proportion of infected midguts and also the number of melanised oocysts per midgut.

Midguts dissected on day 14 p.i. showed no significant differences in oocyst and sporozoite numbers between any of the transgenic parasite lines and Pbwt parasites (Table 1), indicating that both heterologous PgCSP and the chimeric proteins function normally during sporozoite ontogeny in the mosquito vector *A. stephensi*. However, at day 21 p.i., *PgCS*SN parasites showed a significant reduction in the number of salivary gland sporozoites compared to both Pbwt and *PgCS*DHFR control parasites, similar to the results previously reported for mosquitoes infected with *PgCS*-replacement *P. berghei* parasites [29]. Likewise, *PbCS/PbRR* parasites showed a striking and significant reduction in salivary gland sporozoites compared to Pbwt and *PgCS*DHFR parasites (Table 1). Furthermore, no significant difference was observed between *PgCS*SN and *PbCS/PbRR* clones 4 (p>0.09), although the difference between *PgCS*SN and *PbCS/PbRR* clone 5 was significant (p<0.03). However, this result for *PgCS/PbRR* clone 5 may have been due to contaminating hemolymph sporozoites or a greater number of sporozoites adhering to the outside of the glands.

The low numbers of salivary gland sporozoites in mosquitoes infected with *PgCS/PbRR* parasites suggests that the replacement...
Figure 2. Generation and southern blot analysis of transgenic PgCS/PbRR parasite lines. (A) Schematic representation of (i) the PgCS/PbRR targeting construct, (ii) the wt PbCS locus and (iii) the targeted locus after recombination between the PbCS 5'UTR and 3'UTR sequences. The vertically dashed box indicates the 1.13 kb 5'UTR sequence used in the construct and the horizontally dashed boxes indicate the 0.3 kb and 0.85 kb 3'UTR sequences between which the TgDHFR-TS selectable marker cassette (light grey) was inserted in the construct. The PgCS/PbRR chimeric gene contains the PgCS N- and C-terminal regions (dark grey boxes) and the PbCS repeat region (white box) flanked by the SpeI (S) and XhoI (X) sites. In the wt PbCS locus the white box indicates the full PbCS gene. Thick black lines indicate the probes used in southern blots. E: EcoRV site. (B) Southern blot of EcoRV/SpeI (E/S) and EcoRV/XhoI (E/X) digested genomic DNA from Pbwt parasites and transgenic PgCS/PbRR parasites (clones 4 and 5), hybridised with the PbCS 3'UTR probe. Two bands of 4.0 and 1.5 kb were present in Pbwt DNA in both digestions. E/S digested DNA from the PgCS/PbRR clones revealed two bands of 1.1 and 2.0 kb, while E/X digested DNA revealed two bands of 0.6 and 2.0 kb, demonstrating the replacement of the endogenous PbCS gene with the targeted construct. (C) The same membrane was then hybridised with the PgCS N-terminal probe (PgCS-Nt), encompassing the entire N-terminal region of PgCS. No band was present in Pbwt DNA. However, a band of 3.1 kb or 3.6 kb was present in the E/S or E/X digested transgenic DNA, respectively.

doi:10.1371/journal.pone.0032524.g002
Figure 3. Generation and southern blot analysis of transgenic PbCS/PgCT parasite lines. (A) Schematic representation of (i) the PgCS/PbRR targeting construct, (ii) the wt PbCS locus and (iii) the targeted locus after recombination between the PbCS repeat region (white box) and the PbCS 3′UTR (horizontally dashed box). The PbCS/PgCT chimeric gene contains both the PbCS N-terminal and repeat regions (white boxes) and the PgCS C-terminal region (dark grey box). The light grey box indicates the TgDHFR-TS selectable marker cassette. Thick black lines indicate the probes used in southern blots. E = EcoRV site, S = SpeI site and X = XhoI site. (B) Southern blot of EcoRV/SpeI (E/S) and EcoRV/XhoI (E/X) digested genomic DNA from Pbwt parasites, transgenic PgCS/PbRR clone 4 parasites and PbCS/PgCT parasites (clones 3 and 6), hybridised with the PbCS 3′UTR probe. PgCS/PbRR parasites acted as a control for the presence of both the SpeI and XhoI sites in the CS chimeric gene. Both PbCS/PgCT clones contained a gene with the XhoI site but lacked the SpeI site, as demonstrated by the presence of the 4.0 and 2.0 kb bands after E/S digestion and the 2.0 and 0.6 kb bands after E/X digestion, indicating the 5′ cross-over event had occurred between the repeat regions. (C) Southern blot of E/S and E/X digested genomic DNA, hybridised with the PbCS N-terminal region probe. A band of 4.0 kb was detected in both the Pbwt DNA and E/S digested DNA from the PbCS/PgCT clones, demonstrating the presence of the PbCS N-terminal sequence in the transgenic parasites. Genomic DNA from the PbCS/PgCT clones, digested with E/X, revealed a band of 3.5 kb, indicating the presence of the XhoI site. No bands were visible in PgCS/PbRR transgenic parasite DNA due to the absence of the PbCS N-terminal sequence.

doi:10.1371/journal.pone.0032524.g003
of the PgCS repeat region with the homologous PbCS repeat region is not sufficient to rescue salivary gland invasion. In contrast, the PbCS/PgCT transgenic parasites invaded the mosquito salivary glands normally. These parasites contain only the C-terminal sequence of PgCSP, which appears to function normally in A. stephensi salivary gland infection. The results suggest that the N-terminal region plays an important role in salivary gland infection, although it is still possible that repeat region residues co-operate with N-terminal residues in infectivity. This is in agreement with previous studies, which used recombinant N-terminal peptides to demonstrate a role for the region in salivary gland binding [13,22].

We also investigated the infectivity of midgut sporozoites in C57BL/6 mice. Only one out of two mice injected with 500,000 Pbwt sporozoites became parasitaemic, with a pre-patent period of 6.0 days (Table 3). This is consistent with the known lesser infectivity of midgut sporozoites compared to salivary gland sporozoites [31]. A pre-patent period between 7.0 and 8.0 days was observed after injection of 500,000 PbCS/DHFR or PbCS/PgCT sporozoites, demonstrating a similar delay compared to Pbwt sporozoites.

### Infectivity of the transgenic sporozoites for the vertebrate host

To determine the infectivity of the transgenic parasites for the vertebrate host, salivary gland and midgut sporozoites, collected 21 days p.i., were injected intravenously into C57BL/6 mice. All mice injected with Pbwt salivary gland sporozoites developed a parasitaemia, with a pre-patent period ranging from 3.5 to 4.6 days for mice injected with 5,000 and 1,000 sporozoites respectively (Table 2). Interestingly, for the PbCS/DHFR transgenic parasites, only injection with 5,000 sporozoites resulted in a 100% infection rate, and the pre-patent period was longer, ranging from 5.3 to 6.5 days after injection of 5,000 or 1,000 PbCS/DHFR sporozoites, respectively. A 1 day delay in the pre-patent period indicates a 90% decrease in the infective inoculum [30]. This difference in infectivity between Pbwt and PbCS/DHFR parasites suggests a moderate effect on vertebrate host infection due to the presence of the selectable marker cassette in the CS locus.

Mice injected with 5,000 sporozoites, from salivary gland preparations of either PgCSSX or PgCS/PbRR infected mosquitoes, did not develop a parasitaemia, demonstrating that the replacement of the PgCS repeat region with the homologous wildtype PbCS repeat region is also unable to rescue vertebrate infectivity.

The PbCS/PgCT clones had very similar infection rates and pre-patent periods compared to the PbCS/DHFR clones, indicating that the N-terminal sequence is also important for vertebrate infectivity. Moreover, the PgCSP C-terminal sequence appears to function efficiently in vertebrate infectivity, despite the fact that only 39 out of the 85 amino acids in the C-terminus of CSP are conserved between P. berghei and P. gallinaceum, including 10 of the 18 Region II residues (Figure 1B).

### Table 1. Transgenic parasite development in the Anopheles stephensi mosquito vector.

| Parasite               | Midgut oocysts | Midgut sporozoites | Sporozoites/oocyst | Salivary gland sporozoites | Salivary gland sporozoites/oocyst |
|------------------------|----------------|--------------------|--------------------|---------------------------|-----------------------------------|
| Pbwt                   | 182 ± 42       | 12,174 ± 9,070     | 63 ± 79            | 28,412 ± 8,167            | 134 ± 14                          |
| PbCS/DHFR cl9          | 195 ± 105      | 26,021 ± 40,551    | 144 ± 217          | 25,626 ± 5,185            | 154 ± 70                          |
| PbCS/DHFR cl10         | 190 ± 47       | 15,377 ± 6,451     | 89 ± 53            | 14,447 ± 4,503            | 83 ± 40                           |
| PgCSSX cl1             | 189 ± 93       | 6,447 ± 5,221      | 36 ± 27            | 297 ± 336a               | 2 ± 2                             |
| PgCS/PbRR cl4          | 202 ± 66       | 14,844 ± 6,773     | 86 ± 69            | 922 ± 697b              | 6 ± 5                             |
| PgCS/PbRR cl5          | 194 ± 32       | 13,892 ± 8,871     | 68 ± 37            | 1,276 ± 300b             | 7 ± 3                             |
| PbCS/PgCT cl3          | 207 ± 77       | 33,821 ± 32,294    | 240 ± 311          | 15,779 ± 3,832           | 80 ± 17                           |
| PbCS/PgCT cl6          | 248 ± 55       | 32,520 ± 22,484    | 133 ± 99           | 18,291 ± 8,231           | 78 ± 47                           |

*aSignificant difference compared to Pbwt and PbCS/DHFR transgenic parasites; *p < 0.01.  
*bSignificant difference compared to PgCSSX; *p < 0.03.

A. stephensi mosquitoes were fed on mice infected with one of the transgenic clones or Pbwt parasites. Values represent the mean ± S.D. of at least three independent experiments, each with a minimum of 50 mosquitoes.

### Table 2. Infectivity of salivary gland sporozoites for the vertebrate host.

| Parasite               | Sporozoites injected | Mice infected | Pre-patent perioda |
|------------------------|----------------------|---------------|--------------------|
| Pbwt                   | 1,000                | 5/5           | 4.6                |
|                        | 3,000                | 3/3           | 4.0                |
|                        | 5,000                | 3/3           | 3.5                |
| PbCS/DHFR cl9          | 1,000                | 1/6           | 6.0                |
|                        | 3,000                | 4/6           | 6.0                |
|                        | 5,000                | 4/4           | 5.5                |
| PbCS/DHFR cl10         | 1,000                | 2/4           | 6.5                |
|                        | 3,000                | 2/4           | 6.0                |
|                        | 5,000                | 3/3           | 5.3                |
| PgCSSX cl1             | 5,000                | 0/3           | -                  |
| PgCS/PbRR cl4          | 5,000                | 0/5           | -                  |
| PgCS/PbRR cl5          | 5,000                | 0/5           | -                  |
| PbCS/PgCT cl3          | 1,000                | 0/3           | -                  |
|                        | 3,000                | 3/4           | 5.7                |
|                        | 5,000                | 5/6           | 5.5                |
| PbCS/PgCT cl6          | 1,000                | 1/3           | 6.0                |
|                        | 3,000                | 3/4           | 6.0                |
|                        | 5,000                | 4/5           | 5.5                |

*aPre-patent period is the number of days between injection and first appearance of the parasites in the peripheral blood.

C57BL/6 mice were injected intravenously with different numbers of Pbwt or transgenic sporozoites collected on day 21 p.i. from A. stephensi salivary gland preparations. The number of mice that became infected and the pre-patent period were both recorded.
parasites as that observed after the injection of salivary gland preparation sporozoites, \( \text{PgCS/Pb}^{\text{RR}} \) and \( \text{PgCS}^{\text{SS}} \) midgut sporozoites never infected mice (Table 3).

### CSP expression in transgenic parasite lines

Immunofluorescence assays (IFA) were carried out to analyse both CSP expression and gliding motility of midgut sporozoites, since \( \text{PgCS/Pb}^{\text{RR}} \) and \( \text{PgCS}^{\text{SS}} \) transgenic parasites do not appear to invade the salivary glands. Freshly dissected sporozoites were spotted onto a glass slide and either left at room temperature (RT) or placed at 37°C for 30 minutes to induce gliding motility [32]. The parasites were then allowed to react with either a monoclonal antibody directed against the PhCSP repeat region, a polyclonal antibody directed against the \( \text{PgCSP} \) N-terminal region, or a polyclonal antibody directed against the \( \text{PgCSP} \) repeat region antibody (Figure 4 and S3).

Sporozoites from each of the transgenic clones, except \( \text{PgCS}^{\text{SS}} \) and \( \text{PgCS} \) replacement parasites, showed a clear and uniform surface staining when incubated with the PgCSP antibody. A ladder of bands, weaker in intensity and ranging in size between ~30 and 46 kDa, was also present and has previously been described [36,37]. These results demonstrate that the CSPs in the transgenic parasite lines are expressed and processed similarly to CSP in \( \text{Pbwt} \) parasites.

Incubation with the \( \text{PgCSP} \) N-terminal region antiserum revealed only the high MW form, corresponding to the CS precursor, in the \( \text{PgCS/Pb}^{\text{RR}} \) and \( \text{PgCS}^{\text{SS}} \) parasite lines, in agreement with \( \text{N-terminal} \) region cleavage to yield the mature, processed form of CSP, containing the repeat region and C-terminal region. The band present in the \( \text{PgCS/Pb}^{\text{RR}} \) parasites appears to be slightly bigger than the expected ~54 kDa band (revealed after incubation with the PhCSP repeat region antibody). This difference in size is likely due to the fact that the PhCSP repeat region is extremely proline rich and this has been shown to be responsible for anomalous migration patterns of proteins in SDS-PAGE [38].

### Discussion

The aim of this work was to investigate the role of the CSP repeat region and the amino terminal region in the recognition of species-specific vector and host receptors. In previous studies, transgenic \( P. \) \textit{berghei} parasite lines, in which either the entire endogenous CS gene or the repeat region was replaced with the \( P. \) \textit{falciparum} orthologous sequence, both showed a ten fold reduction in A. \textit{stephensi} salivary gland invasion [27,29], suggesting a functional role of the repeat sequence in the recognition of species-specific host receptors. Our results indicate that the repeat region, on its own, is unlikely to represent the sporozoite species-specific salivary gland or hepatocyte ligand, because the replacement of the \( \text{PgCS} \) repeat region with the \( \text{PbCS} \) repeat region in the \( \text{PgCS/Pb}^{\text{RR}} \) transgenic parasites doesn’t rescue \( \text{PgCS/Pb}^{\text{RR}} \) parasites, when analysed with the antibody against the PhCSP repeat region, displayed clear surface CSP expression (Figure 4) [33]. Similarly, \( \text{PgCS}^{\text{SS}} \) and \( \text{PgCS} \) replacement sporozoites, incubated with a serum against the PhCSP repeat region, revealed normal surface staining (Figure 4), and also the presence of clumps of immunoreactive material either outside the parasite body or in proximity to its surface, following incubation at 37°C (Figure S3) [29], indicating that the introduction of the two restriction endonuclease sites in the \( \text{PgCS} \) sequence had no obvious effect on protein expression and release.

These IFA results are in agreement with recent data that report the absence of the N-terminal CSP sequence on the surface of \( P. \) \textit{berghei} oocyst sporozoites [34]. The two antibodies are therefore reacting with different processed forms of CSP: the repeat region antibodies with a lower molecular weight (MW) form, lacking the N-terminal region and associated with the surface of the sporozoite, and the PgCSP N-terminal region serum with a higher MW form present in the cytoplasm.

Salivary gland sporozoites from \( \text{Pbwt}, \text{PbCS}^{\text{OHFR}} \) and \( \text{PgCS/P}^{\text{CT}} \) infected mosquitoes, incubated with the PhCSP repeat region antibody, displayed a regular CSP surface expression and the characteristic circular gliding motility (Figure S4), with no differences observed either in the frequency of motile sporozoites or the percentage forming trails of at least one complete loop.
sporozoite infectivity of either *A. stephensi* salivary glands or vertebrate hepatocytes. However, it is still possible that sequences in the N-terminal region and repeat region cooperate in, and are both required for, sporozoite infectivity.

The *P. berghei* transgenic parasites bearing a chimeric CSP displaying the *P. falciparum* CS repeat region, also had the RI motif and 14 residues upstream (RI-plus) exchanged with those of *P. falciparum* [27]. The change in either the repeat region or RI-plus could have been responsible for the 10-fold decrease in salivary gland invasion observed with these parasites. Although the RI core is the same between the two species (KLKQP), RI-plus differs between *P. berghei* and *P. falciparum*. In both *P. falciparum* and *P. berghei* nine of the fourteen residues are charged, indicating that the regions might be involved in interactions with host receptors. Nevertheless, it is possible that the repeat region has a function in infectivity acting in concert with other CSP regions. The CSP repeat region may fulfill a structural role, with the repeats from neighboring CSP molecules interlocking to form a rigid sheath surrounding the parasite [39]. Proline-rich tandem repeats generally form extended structures and flexible regions in proteins, and have been shown to function both as structural elements and in binding processes [40].

*PbCS/Pg** parasites, containing both the *PbCS* N-terminal and repeat regions, were not impaired in salivary gland or vertebrate infectivity, pointing to a role for the N-terminal region in infection. Indeed, sera against the *P. falciparum* and *P. berghei* CSP N-terminal regions have been shown to inhibit sporozoite invasion of hepatocytes *in vitro* and HepG2 cells [41]. In previous investigations, a role in salivary gland infectivity was implied based on binding inhibition experiments, in which specific peptides were

---

**Figure 4. Sporozoite CSP expression.** Confocal immunofluorescence microphotographs of transgenic midgut sporozoites incubated at room temperature and developed with either a monoclonal antibody directed against the PbCSP repeat region (Pb-RR), a serum directed against the PgCSP N-terminal region (Pg-Nt), or a serum directed against the PgCSP repeat region (Pg-RR). Antibodies against the PbCSP and PgCSP repeat regions showed surface expression of the CSPs, whereas antibody against the PgCSP N-terminal region revealed mainly an intracellular pattern of expression. doi:10.1371/journal.pone.0032524.g004

**Figure 5. Western blot analysis of CSP expression and processing in transgenic midgut sporozoites 18 days post-infection.** CSP expression was revealed by incubation with either a monoclonal antibody directed against the PbCSP repeat region (PbCS-RR) or a serum directed against the PgCSP N-terminal region (PgCS-Nt). As a control, midgut lysates from uninfected mosquitoes were also analysed. Antibody against the PbCSP repeat region reveals a higher molecular weight precursor polypeptide and a lower molecular weight processed polypeptide. A ladder of degradation products is also visible. Antibody against the PgCSP N-terminal region reveals only the higher molecular weight protein. doi:10.1371/journal.pone.0032524.g005
analysed for their ability to block recombinant CSP and sporozoite binding to the glands [13,22]. However, the results of peptide inhibition studies can be due to steric hindrance. Therefore, gene targeting provides a more reliable system for determining the function of protein domains.

IFA analysis with a serum directed against the PgCSP N-terminal region appeared to localise the PgCS/PbRR and PgCS\textsuperscript{SN} proteins mainly to the intracellular compartment, in contrast to antibodies against the PbCSP and PgCSP repeat regions, which revealed fluorescence at the surface of transgenic sporozoites (Figure 4). The results indicate that two forms of CSP are present in our transgenic lines: a full length protein localised intracellularly and a processed form, lacking the N-terminal region, and expressed uniformly on the sporozoite surface. This suggests possibly an intracellular site of CSP processing or alternatively, the protein may be cleaved either during its release from the apical organelles, before translocation onto the sporozoite surface, or after contact with target cells. Contradictory results support both intracellular [35,42,43] and surface [44,45] sites of CSP cleavage. In Toxoplasma gondii, the N-terminal region of the adhesive protein, MIC2, is trimmed prior to secretion [46]. Another T. gondii protein, MIC3, which is re-localised to the surface of the parasite during invasion, is synthesised with an N-terminal propeptide that is cleaved during trafficking to the microneme. The processing was shown to be required for the protein to function as an adhesin [47] and it is possible that a similar mechanism operates in Plasmodium CSP.

Western blot analysis demonstrated that at least a large part of the N-terminal region is cleaved from the precursor polypeptide in each of the transgenic lines. Furthermore, data suggests that the protease that mediates CSP cleavage is parasite derived rather than host derived [45], which is compatible with an intracellular site of processing. The protease may therefore differ between P. berghei and P. gallinaceum parasites, which could in turn affect the correct processing of the transgenic CS proteins. However, the results indicate that the P. berghei protease is able to similarly cleave PbCSP and the chimeric CS proteins.

Our results demonstrate that the N-terminal region of CSP is important for infectivity, which suggests that at least part of this sequence is likely to be present on the sporozoite surface, possibly acting as a ligand for host receptors. This observation is partially in agreement with the recent results from Coppi et al. [34], in which they identify a higher MW CSP on the surface of the sporozoites. We have tried to determine the precise cleavage site in our transgenic lines by sequencing the low MW form of CSP, however we were unable to obtain enough material.

Recent results indicate that RI plays a critical role in CSP processing either because it is required for efficient cleavage or because it contains the cleavage site [34]. RI in P. gallinaceum (NLNQP) differs from mammalian Plasmodium spp. RI (KLKQP) and yet the PgCS/PbRR protein is still processed, probably by the same proteolytic enzyme. Both the high and low MW CSP bands of the PgCS/PbRR parasites run slightly higher compared to the equivalent bands of the PbCS/Pg\textsuperscript{CT} parasites in Western blot analysis (Figure 5). This is in part due to the fact that the chimeric proteins have different sizes: PgCS/PbRR and PbCS/Pg\textsuperscript{CT} contain 382 and 347 amino acids respectively. If the cleavage site is located at RI, one would expect the low MW bands from these two parasite lines to be the same size, since the processed CSPs in both these lines would contain the PbCS repeat region and the PgCS C-terminal region. Only the high MW bands, representing the precursor polyproteases, would differ in size. However, in our Western blot analysis, both the high and low MW bands from the PgCS/PbRR parasites appear to have larger MWs compared to the equivalent bands in the PbCS/Pg\textsuperscript{CT} parasites. This could be explained if the cleavage site is located upstream of RI, in the N-terminal region: an extra 25 amino acids are present just upstream of RI in the PgCSP sequence compared to the PbCSP sequence (Figure 1A), and this could explain the greater MW of the processed protein in PgCS/PbRR parasites compared to that of PbCS/Pg\textsuperscript{CT} parasites.

The sequence just upstream of RI contains a stretch of charged residues that, if included in the processed form of the protein, may act as a ligand. A peptide from PICSP, spanning a region just upstream of RI (AA 93 to 113), was found to serve as a ligand for both hepatocytes [21] and salivary glands [13,22]. Importantly, recognition of the N-terminal peptide (PICSP(95, 110)) by sera from children living in a malaria-endemic region was associated with protection from disease [41]. The sequence of both RI and RI-plus varies considerably between P. berghei and P. gallinaceum (Figure 1A). In PbCSP, RI and the first 25 residues upstream of it contain 14 charged residues compared to the corresponding PgCSP sequence that contains only seven charged residues and this may explain the difference in infectivity observed between the PgCS/PbRR and the PbCS/Pg\textsuperscript{CT} parasites.

The numerous investigations into the functions of CSP’s conserved motifs, RI and RII, have by no means led to a broad understanding of CSP’s interactions during host infection. More recent work on CSP has focused on the N-terminal region of the protein [41] and the stretches of positively charged residues found throughout this region [19,22]. The present investigation highlights, in vivo, a role for N-terminal residues in sporozoite infectivity in both the vertebrate and invertebrate hosts. These parasites could also provide a valuable rodent model to investigate the emerging role of the CSP N-terminal region in the induction of protective immune responses.

Materials and Methods

Ethics statement

Animal work conducted at Imperial College was performed according to UK Home Office Regulations and approved under Home Office License PPL 70/6453. Studies carried out at Perugia University have been performed according to the D.L 27 January 1992, n. 116, Italian legislation, and approved under Ethics Committee Licence n. PR 0161.

DNA constructs

The targeting constructs pPgCS\textsuperscript{SN}, pPgCS/PbRR and pPbCS\textsuperscript{DHFR} generated in this study contained the following structural elements: (i) the first 1,130 nucleotides of the PbCS 5’ UTR sequence immediately upstream of the start codon; (ii) PgCS, PhCS or a chimeric form of the CS coding sequence and (iii) the first 1,150 nucleotides of the PbCS 3’ UTR sequence immediately downstream of its stop codon, in which the T. gondii dihydrofolate reductase/thymidylate synthase (TgDHFR/TS) drug selectable marker cassette (5,150 bp) was inserted at its HindIII site.

All three constructs were generated from a targeting construct, pPgCS, already available in our laboratory which contains the full PgCS coding sequence [29]. The SpeI and XhoI sites were introduced on either side of the PgCS repeat region by PCR based site-directed mutagenesis. Primers used to introduce SpeI were: For1 5’-GAGAAAAATTTGTGTAATCTTACACCA-ACTAGTTGGAGGAAATGGTGTTGTTCAACCTCACCTGCTGCTG-3’ (SpeI is underlined) and Rev1 complementary to the forward primer. Primers used to introduce XhoI were: For2 5’-CTGAGA-GAGAAAGGGAGATGAAACCATTACACATGATCGAGG-
CAACTCAAGAAGAATAGATAATATTAAAAG-3' (XhoI is underlined) and Rev2 complementary to the forward primer.

The 1.02 kb PbCS gene was amplified from *P. berghei* genomic DNA (Anka strain, clone 2.34) and sequenced. Forward and reverse primers were designed to amplify the PbCS repeat region from this sequence, introducing the SpeI and XhoI sites at either end of the repeat region (Spefor 5'-TAATTAAAAATTTAGACACACATC-3' and Speback 5’-GCAGAGGGAATTCTAGCTCA-3') (XhoI is underlined). The PbCS repeat region was then replaced with the targeting construct, via SpeI and XhoI digestions. Sequencing analysis and alignment with the wild type *P. berghei* (GenBank: M14145) or *P. gallinaceum* (GenBank: 65959) sequences confirmed the correct CS genes inserted in each construct.

**Parasite transformation**

Plasmids pPgCSxx and pPgCS/PbRR were digested with XhoI to release the ~6.6 kb targeting insert from the plasmid backbone and the insert was purified by gel electrophoresis. Purified schizonts of the *P. berghei* ANKA strain (clone 2.34) were transformed with 5 µg of targeting DNA using an Amaxa Gene Pulser set at program U33. Mutant parasites were obtained by the standard method of drug (pyrimethamine) selection in mice [48].

**Southern blot analysis**

Genomic DNA was isolated from parasites as previously described [33]. 1–3 µg of genomic DNA was digested with EcoRV alone or in combination with either SpeI or XhoI, separated on an agarose gel and blotted onto a nylon Hybond-N+ membrane (Amersham). The following DNA fragments were used as probes: (a) the 1.15 kb fragment of the PbCS 3' UTR from the targeting constructs, (b) the entire N-terminal sequence of the PbCS coding region, (c) the entire N-terminal sequence of the pgCS coding region and (d) a 520 bp fragment amplified from the TdDHFR/TS coding sequence with the primers TgFor123 (5’-AGAGGGGGCATGCGGCTATCACCA-3') and TgRev124 (5’-TTGAAGAGATTCTACTCTCCG-3'). All hybridization experiments were carried out as previously described [33,49].

**Sequencing of genomic DNA**

The primers PbCS5UTR3’F (5’-CCCTCGACATAAGAATACCC-3’) and PbCS3’UTR5’R (5’-GTTTAGAACGCTCAATATGAT-3’), which anneal to the 5’ and 3’ UTR sequences of the CS locus, were used to amplify the full length CS gene from blood stage transgenic parasite genomic DNA, isolated from sporozoite-infected mice where possible. The PCR products were then sequenced directly (MWG-Biotech).

**Parasite development in the mosquito**

Female mosquitoes (4–6 days old) of *A. stephensi* (strain sd500), were fed for 30 minutes on either wild type (wt) or transgenic parasite infected BALB/c mice (six- to eight-week-old female Balb/c from Harlan Sprague) with a parasitaemia ranging from 5% to 10%. Mosquitoes were dissected at days 14 and 21 post infection (p.i.) to determine the presence of oocysts and the number of parasites in the midguts and salivary glands.

**Parasite infectivity in mice**

Midgut and salivary gland sporozoites were diluted with RPMI and intravenously (i.v.) injected into C57BL/6 mice (six- to eight-week-old female C57BL/6 from Charles River) in order to assess vertebrate infectivity. After sporozoite injection, blood samples were withdrawn from the tails at regular intervals up to 15 days p.i. and a minimum of 10,000 erythrocytes were examined on Giemsa stained blood smears. The pre-patent period was determined as the number of days between sporozoite injection and when parasites were first detected in the blood.

**Western blot analysis**

Total proteins were extracted from infected (day 18 p.i.) and uninfected *A. stephensi* mosquito midguts using reducing sample buffer and separated on a 12% gel by SDS-PAGE. Blots were incubated for 1 hour at RT with the appropriate primary antibody: either a 1:200 dilution of the monoclonal antibody 3D11 raised in mice against the PbCSP repeat region [11] or a 1:200 dilution of a mouse serum raised against the PgCSP N-terminal region (a gift from Dr. Dharment R athore), then developed with the enhanced chemiluminescence detection system, according to the manufacturer’s instructions (Amersham Pharmacia).

**Immunofluorescence analysis**

Freshly dissected sporozoites collected at day 21 p.i. from mosquito midguts and salivary glands were diluted in RPMI 1640 and spotted onto multiwell microscope slides. The slides were either incubated at 37°C, to induce sporozoite gliding [32], or at RT for 30 minutes. Parasites were fixed with 1% formaldehyde in 1× PBS and blocked with 1% BSA in 1× PBS for 30 minutes at RT. The slides were then incubated with one of three primary antibodies: the monoclonal antibody against the PbCSP repeat region [11], the serum against the PgCSP N-terminal region or a 1:1000 dilution of a rabbit serum raised against the PgCSP repeat region. Antibody bound to the parasites or their trails was revealed by incubation with fluorescein isothiocyanate (FITC)-conjugated secondary antibody (Becton Dickinson). Analysis of expression was carried out using a Leica TCS SP 2 confocal microscope.

**Supporting Information**

**Figure S1 Generation and southern blot analysis of transgenic PgCSxx parasite lines.** (A) Schematic representation of (i) the PgCSxx targeting construct, (ii) the wt PbCS locus and (iii) the targeted locus after recombination between the PbCS 5’UTR and 3’UTR sequences. The vertically dashed box indicates the 1.13 kb 5’UTR sequence used in the construct and the horizontally dashed boxes indicate the 0.3 kb and 0.85 kb 3’UTR sequences between which the TgDHFR/TS selectable marker cassette (light grey) was inserted in the construct. The PgCSxx gene contains the full PgCS coding sequence (dark grey) into which the SpeI (S) and XhoI (X) sites were inserted on either side of the repeat region. Thick black lines indicate the probes used in southern blots. E = EcoRV. (B) Southern blot of EcoRV digested genomic DNA from Pbw parasites and PgCS-replacement parasites (clone 14, [29]), that acted as negative and positive controls respectively, and transgenic PgCSxx parasites (clones 1 and 2). The blot was first hybridised with the PbCS 3’UTR probe, containing the full 1.15 kb fragment of the PbCS 3’UTR sequence present in the targeting construct. The 3’UTR probe hybridised with bands of 4.0 and 1.5 kb in digested Pbw DNA and with bands of 4.2 and 2.0 kb in the transgenic parasite DNA. The size shift from 4.0 to 4.2 kb is due to the longer PgCS coding sequence. The 2.0 kb band indicates the presence of the TgDHFR/TS cassette in the PbCS locus. The membrane was also hybridized with probes encompassing the TgDHFR/TS gene (C), the PbCS
gene (D) and the PgCS gene (E). The TgDHFR/TS probe revealed a band of 4.6 kb only in transgenic DNA (C). The PbCS probe revealed the 4.0 kb band only in the Pbow DNA (D) while the PgCS probe bound to the correct 4.2 kb band only in the transgenic parasite DNA (E).

Figure S2 Generation and southern blot analysis of transgenic PbCS\textsuperscript{DHFR} parasite lines. (A) Schematic representation of (i) the PgCS/Pb\textsuperscript{DHFR} targeting construct, (ii) the wt PgCS locus and (iii) the targeted locus after recombination between the two PbCS 3' UTR sequences (horizontally dashed boxes) flanking the TgDHFR/TS selectable marker cassette (light grey box). The targeted locus therefore carried the endogenous wt PgCS gene (white box) and, inserted in the 3'UTR, the TgDHFR/TS selectable marker cassette. Thick black lines indicate the probes used in southern blots. E: EcoRV site, S: SpeI site and X: XhoI site. (B) Southern blot of EcoRV/SpeI digested genomic DNA from Pbow parasites and transgenic PbCS\textsuperscript{DHFR} parasites (clones 9 and 10), hybridised with the PbCS 3' UTR probe. (C) Southern blot of EcoRV/XhoI digested genomic DNA hybridised with the PbCS N-terminal probe. Neither clone contained the SpeI or XhoI sites, as demonstrated by the presence of the 4.0 kb band in all lanes, indicating recombination had occurred between the short 0.3 kb PbCS 3' UTR sequence upstream of the marker cassette. A second band in the transgenic parasite DNA of 2.0 kb, compared to the 1.5 kb band in the Pbow DNA, indicated the insertion of the TgDHFR/TS cassette in the PbCS locus.

Figure S3 Sporozoite CSP expression and motility. Confoal immunofluorescence microphotographs of P. berghei wt and transgenic midgut sporozoites incubated at 37°C to induce motility and developed with either a monoclonal antibody directed against the PbCSP repeat region (Pb-RR), a serum directed against the PgCSP N-terminal region (Pg-Nt), or a serum directed against the PgCSP repeat region (Pg-RR). Sporozoites shed trails of material recognised by antibody against the PbCSP repeat region. Antibody against the PgCSP N-terminal region (Pg-Nt) revealed mainly an intracellular pattern of expression, and no trails, for the PgCS/Pb\textsuperscript{DHFR}, PgCS\textsuperscript{SSN} and PgCS replacement parasites. The antibody against the Pg-RR revealed the presence of clumps of immunoreactive material either outside the parasite body or in proximity to its surface.

Figure S4 Salivary gland sporozoite CSP expression and motility. Confocal immunofluorescence microphotographs of P. berghei wt and transgenic salivary gland sporozoites incubated at either room temperature (RT) or 37°C and developed with an antibody directed against the PbCSP repeat region (Pb-RR). The antibody revealed surface expression in PgCS\textsuperscript{DHFR} and PbCS/ Pg\textsuperscript{CT} salivary gland sporozoites, similar to P. berghei wt salivary gland sporozoites. Sporozoites incubated at 37°C shed trails of material recognised by the anti-PbCSP repeat region antibody.

Author Contributions
Conceived and designed the experiments: CA RS. Performed the experiments: CA. Analyzed the data: CA AM CE TD FB AC RS. Wrote the paper: CA RS.

References
1. Nardin E, Zavala F, Nussenzweig V, Nussenzweig RS (1999) Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials. Parasitology 41: 397–402.
2. Birkeir AM, Lyons K, Schmidt A, Boyd D, Oliveira GA, et al. (2002) A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect Immun 70: 6669–6670.
3. Ballou WR, Hoffmann SL, Sherwood JA, Hollingdale MR, Neva FA, et al. (1987) Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1: 1277–1281.
4. Harrington IA, Clyde DF, Lesonsky G, Cortesia M, Murphy JR, et al. (1987) Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328: 257–259.
5. Ballo WR (2009) The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immun 31: 492–500.
6. Nagasawa H, Procell PM, Atkinson CT, Campbell GH, Collins WE, et al. (1998) Immunogold localization of circumsporozoite protein of the malaria parasite of Plasmodium falciparum during sporogony in Anopheles stephensi midguts. Eur J Cell Biol 66: 18–24.
7. Stewart MJ, Navrot RJ, Schulman S, Vanderberg JP (1986) Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-antibody binding antibodies. Infect Immun 55: 859–864.
8. Stewart MJ, Vanderberg JP (1988) Malaria sporozoites leave behind trails of circumsporozoite protein during gliding motility. J Protozool 35: 389–393.
9. Pootongpij P, Yoshida N, Nussenzweig V, Nussenzweig RS, Nussenzweig V (1980) Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (PbHR) protect mice against malaria infection. J Exp Med 151: 1501–1513.
10. Yoshida N, Nussenzweig RS, Pootongpij P, Nussenzweig V, Aikawa M (1980) Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207: 71–73.
11. Warburg A, Touray M, Kretti AU, Miller LH (1992) Plasmodium gallinaceum: antibodies to circumsporozoite protein prevent sporozoites from invading the salivary glands of Aedes aegypti. Exp Parasitol 73: 303–307.
12. Sidjanpi SP, Vanderberg JP, Sinnis P (1997) Anopheles stephensi salivary glands bear receptors for region I of the circumsporozoite protein of Plasmodium falciparum. Mol Biochem Parasitol 90: 33–41.
13. Yoshida N, Nussenzweig V, Aikawa M (1980) Virus-expressed, recombinant single-chain antibody blocks sporozoite infection of salivary glands in Plasmodium gallinaceum-injected Aedes aegypti. Am J Trop Med Hyg 62: 427–433.
14. Cerami C, Frevert U, Sinnis P, Takacs B, Clavijo P, et al. (1992) The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell 70: 1021–1032.
15. Cerami C, Frevert U, Sinnis P, Takacs B, Nussenzweig V (1994) Rapid clearance of malaria circumsporozoite protein (CS) by hepatocytes. J Exp Med 179: 695–701.
16. Pinzon-Ortiz C, Friedman J, Esco J, Sinnis P (2001) The binding of the circumsporozoite protein to cell surface heparan sulfate proteoglycans is required for plasmodium sporozoite attachment to target cells. J Biol Chem 276: 26784–26791.
17. Rathore D, McCutchan TF (2000) Heparin can regulate the binding of Plasmodium falciparum circumsporozoite protein. Mol Biochem Parasitol 108: 253–256.
18. Rathore D, Sacci JB, de la Vega P, McCutchan TF (2002) Binding and invasion of liver cells by Plasmodium falciparum sporozoites. Essential involvement of the amino terminus of circumsporozoite protein. J Biol Chem 277: 7092–7096.
19. Ancin JB, Kislinsky Y (2004) A binding site for highly sulfated heparan sulfate on the Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J Biol Chem 279: 21824–21832.
20. Rathore D, Nagarkatti R, Jani D, Chattopadhyay R, de la Vega P, et al. (2005) An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J Biol Chem 280: 20524–20529.
21. Myung JM, Marshall P, Sinnis P (2004) The Plasmodium falciparum circumsporozoite protein is involved in mosquito salivary gland invasion by sporozoites. Mol Biochem Parasitol 133: 53–59.
22. Ying P, Shuklabai M, Patankar MS, Clavijo P, Beavis RC, et al. (1997) The malaria circumsporozoite protein: interaction of the conserved regions I and II-plus with heparin-like oligosaccharides in heparan sulfate. Exp Parasitol 85: 1461–1472.
23. Frevert U, Sinnis P, Cerami C, Shreffler W, Takacs B, et al. (1993) Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J Exp Med 177: 1297–1298.
24. Sinnis P, Clavijo P, Froyo D, Chai RT, Cerami C, et al. (1994) Structural and functional properties of region II-plus of the malaria circumsporozoite protein. J Exp Med 180: 297–306.
26. Nussenzweig V, Nussenzweig RS (1989) Rationale for the development of an engineered sporozoite malaria vaccine. Adv Immunol 45: 283–334.

27. Persson C, Oliveira GA, Sultan AA, Bhanot P, Nussenzweig V, et al. (2002) Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J Immunol 169: 6681–6685.

28. Rathore D, McGuthian TF, Garbozzi DN, Toida T, Hermanz MJ, et al. (2001) Direct measurement of the interactions of glycosaminoglycans and a heparin decasaccharide with the malaria circumsporozoite protein. Biochemistry 40: 11518–11524.

29. Tewari R, Rathore D, Crisanti A (2003) Motility and infectivity of Plasmodium berghei sporozoites expressing avian Plasmodium gallinaceum circumsporozoite protein. Cell Microbiol 5: 699–707.

30. Gantt SM, Myung JM, Briones MR, Li WD, Corey EJ, et al. (1998) Proteasome inhibitors block development of Plasmodium spp. Antimicrob Agents Chemother 42: 2731–2738.

31. Vanderberg JP (1975) Development of infectivity by the Plasmodium berghei sporozoite. J Parasitol 61: 43–50.

32. Spaccapelo R, Naitza S, Robson KJ, Crisanti A (1997) Thrombospondin-related adhesive protein (TRAP) of Plasmodium berghei and parasite motility. Lancet 350: 335.

33. Tewari R, Spaccapelo R, Bistoni F, Holder AA, Crisanti A (2002) Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity. J Biol Chem 277: 47613–47618.

34. Coppi A, Natarajan R, Pradel G, Bennett BL, James ER, et al. (2011) The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J Exp Med 208: 341–356.

35. Yoshida N, Potocnjak P, Nussenzweig V, Nussenzweig RS (1981) Biosynthesis of Pb44, the protective antigen of sporozoites of Plasmodium berghei. J Exp Med 154: 1225–1236.

36. Simonetti AB, Billingsley PF, Winger LA, Sinden RE (1993) Kinetics of expression of two major Plasmodium berghei antigens in the mosquito vector, Anopheles stephensi. J Eukaryot Microbiol 40: 569–576.

37. Boulanger N, Charoenvit Y, Krettli A, Betschart B (1995) Developmental changes in the circumsporozoite proteins of Plasmodium berghei and P. gallinaceum in their mosquito vectors. Parasitol Res 81: 56–65.

38. Robson KJ, Naitza S, Barker G, Sinden RE, Crisanti A (1997) Cloning and expression of the thrombospondin related adhesive protein gene of Plasmodium berghei. Mol Biochem Parasitol 84: 1–12.

39. Godson GN, Ellis J, Svec P, Schlesinger DH, Nussenzweig V (1983) Identification and chemical synthesis of a tandemly repeated immunogenic region of Plasmodium knowlesi circumsporozoite protein. Nature 305: 29–33.

40. Williamson MP (1994) The structure and function of proline-rich regions in proteins. Biochem J 297(Pt 2): 249–260.

41. Bongfen SE, Noaana PM, Offier S, Smith T, Felger I, et al. (2009) The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 27: 328–335.

42. Cochrane AH, Santoro F, Nussenzweig V, Gwadz RW, Nussenzweig RS (1982) Monoclonal antibodies identify the protective antigens of sporozoites of Plasmodium knowlesi. Proc Natl Acad Sci U S A 79: 5651–5655.

43. Santoro F, Cochrane AH, Nussenzweig V, Nardin EH, Nussenzweig RS, et al. (1983) Structural similarities among the protective antigens of sporozoites from different species of malaria parasites. J Biol Chem 258: 3341–3345.

44. Gonzalez-Ceron L, Rodriguez MH, Wirtz RA, Sina BJ, Palomese OL, et al. (1998) Plasmodium vivax: a monoclonal antibody recognizes a circumsporozoite protein precursor on the sporozoite surface. Exp Parasitol 90: 205–211.

45. Coppi A, Pinzon-Oritz C, Hutter C, Sinnis P (2005) The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J Exp Med 201: 27–33.

46. Carruthers VB, Sherman GD, Sibley LD (2000) The Toxoplasma adhesive protein MIC2 is proteolytically processed at multiple sites by two parasite-derived proteases. J Biol Chem 275: 14346–14353.

47. Cerede O, Dubremetz JF, Bout D, Lebrun M (2002) The Toxoplasma gondii protein MIC3 requires pro-peptide cleavage and dimerization to function as adhesin. Embo J 21: 2526–2536.

48. Jane CJ, Ramasar J, Waters AP (2006) High-efficiency transfection and drug selection of genetically transformed blood stages of the rodent malaria parasite Plasmodium berghei. Nat Protoc 1: 346–356.

49. Wengelnik K, Spaccapelo R, Naitza S, Robson KJ, Jane CJ, et al. (1999) The A-domain and the thrombospondin-related motif of Plasmodium falciparum TRAP are implicated in the invasion process of mosquito salivary glands. Embo J 18: 5195–5204.